Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 929170, 16 pages
http://dx.doi.org/10.1155/2015/929170
Review Article

Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases

1Section of Pulmonary & Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
2Department of Cardiology, Deborah Heart and Lung Center, Browns Mills, NJ 08015, USA
3Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA

Received 28 March 2015; Accepted 26 August 2015

Academic Editor: Massimo F. Piepoli

Copyright © 2015 Ayodeji Adegunsoye et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. U. Wells, M. Kokosi, and K. Karagiannis, “Treatment strategies for idiopathic interstitial pneumonias,” Current Opinion in Pulmonary Medicine, vol. 20, no. 5, pp. 442–448, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. C. E. Daniels, E. S. Yi, and J. H. Ryu, “Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis,” European Respiratory Journal, vol. 32, no. 1, pp. 170–174, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. A. K. Boutou, G. G. Pitsiou, I. Trigonis et al., “Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension,” Respirology, vol. 16, no. 3, pp. 451–458, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. C. J. Lettieri, S. D. Nathan, S. D. Barnett, S. Ahmad, and A. F. Shorr, “Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis,” Chest, vol. 129, no. 3, pp. 746–752, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. O. A. Minai, J. F. Santacruz, J. M. Alster, M. M. Budev, and K. McCarthy, “Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis,” Respiratory Medicine, vol. 106, no. 11, pp. 1613–1621, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. S. D. Nathan, O. A. Shlobin, S. Ahmad et al., “Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis,” Respiration, vol. 76, no. 3, pp. 288–294, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Behr and J. H. Ryu, “Pulmonary hypertension in interstitial lung disease,” European Respiratory Journal, vol. 31, no. 6, pp. 1357–1367, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. A. F. Shorr, J. L. Wainright, C. S. Cors, C. J. Lettieri, and S. D. Nathan, “Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant,” European Respiratory Journal, vol. 30, no. 4, pp. 715–721, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Kimura, H. Taniguchi, Y. Kondoh et al., “Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis,” Respiration, vol. 85, no. 6, pp. 456–463, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. T. J. Corte, S. J. Wort, and A. U. Wells, “Pulmonary hypertension in idiopathic pulmonary fibrosis: a review,” Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 26, no. 1, pp. 7–19, 2009. View at Google Scholar · View at Scopus
  11. V. Cottin, J. Le Pavec, G. Prévot et al., “Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome,” European Respiratory Journal, vol. 35, no. 1, pp. 105–111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Bossone, B. D. Bodini, A. Mazza, and L. Allegra, “Pulmonary arterial hypertension: the key role of echocardiography,” Chest, vol. 127, no. 5, pp. 1836–1843, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. M. McGoon, D. Gutterman, V. Steen et al., “Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines,” Chest, vol. 126, no. 1, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. R. J. Barst, M. McGoon, A. Torbicki et al., “Diagnosis and differential assessment of pulmonary arterial hypertension,” Journal of the American College of Cardiology, vol. 43, pp. 40S–47S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. P. G. Yock and R. L. Popp, “Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation,” Circulation, vol. 70, no. 4, pp. 657–662, 1984. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Ben-Dor, M. R. Kramer, A. Raccah et al., “Echocardiography versus right-sided heart catheterization among lung transplantation candidates,” Annals of Thoracic Surgery, vol. 81, no. 3, pp. 1056–1060, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. S. M. Arcasoy, J. D. Christie, V. A. Ferrari et al., “Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease,” American Journal of Respiratory and Critical Care Medicine, vol. 167, no. 5, pp. 735–740, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. L. G. Rudski, W. W. Lai, J. Afilalo et al., “Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography,” Journal of the American Society of Echocardiography, vol. 23, pp. 685–713, 786–788, 2010. View at Google Scholar
  19. M. L. Alkotob, P. Soltani, M. A. Sheatt et al., “Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma,” Chest, vol. 130, no. 1, pp. 176–181, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Pitsiou, C. E. Papadopoulos, H. I. Karvounis et al., “Utility of tissue doppler imaging in predicting outcome in patients with idiopathic pulmonary fibrosis,” Hellenic Journal of Cardiology, vol. 48, no. 3, pp. 143–151, 2007. View at Google Scholar · View at Scopus
  21. T. S. Saba, J. Foster, M. Cockburn, M. Cowan, and A. J. Peacock, “Ventricular mass index using magnetic resonance imaging accurately estimates pulmonary artery pressure,” European Respiratory Journal, vol. 20, no. 6, pp. 1519–1524, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. L. J. M. Kroft, P. Simons, J. M. van Laar, and A. de Roos, “Patients with pulmonary fibrosis: cardiac function assessed with MR imaging,” Radiology, vol. 216, no. 2, pp. 464–471, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. A. M. Groves, T. Win, S. C. Charman, C. Wisbey, J. Pepke-Zaba, and R. A. Coulden, “Semi-quantitative assessment of tricuspid regurgitation on contrast-enhanced multidetector CT,” Clinical Radiology, vol. 59, no. 8, pp. 715–719, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. N. F. Voelkel, R. A. Quaife, L. A. Leinwand et al., “Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure,” Circulation, vol. 114, no. 17, pp. 1883–1891, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. J.-L. Vachiéry, Y. Adir, J. A. Barberà et al., “Pulmonary hypertension due to left heart diseases,” Journal of the American College of Cardiology, vol. 62, no. 25, pp. D100–D108, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Aguero, K. Ishikawa, L. Hadri et al., “Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 307, no. 8, pp. H1204–H1215, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. Y.-Y. Zhao, Y. Liu, R.-V. Stan et al., “Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 17, pp. 11375–11380, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Node, M. Kitakaze, H. Kosaka et al., “Increased release of NO during ischemia reduces myocardial contractility and improves metabolic dysfunction,” Circulation, vol. 93, no. 2, pp. 356–364, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. M. S. Finkel, C. V. Oddis, T. D. Jacob, S. C. Watkins, B. G. Hattler, and R. L. Simmons, “Negative inotropic effects of cytokines on the heart mediated by nitric oxide,” Science, vol. 257, no. 5068, pp. 387–389, 1992. View at Publisher · View at Google Scholar · View at Scopus
  30. D.-L. Dixon, K. M. Griggs, A. D. Bersten, and C. G. De Pasquale, “Systemic inflammation and cell activation reflects morbidity in chronic heart failure,” Cytokine, vol. 56, no. 3, pp. 593–599, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Fireman, N. Vardinon, M. Burke et al., “Predictive value of response to treatment of T-lymphocyte subpopulations in idiopathic pulmonary fibrosis,” European Respiratory Journal, vol. 11, no. 3, pp. 706–711, 1998. View at Google Scholar · View at Scopus
  32. T. Tanabe, S. Kanoh, W. B. Moskowitz, and B. K. Rubin, “Cardiac asthma: transforming growth factor-β from the failing heart leads to squamous metaplasia in human airway cells and in the murine lung,” Chest, vol. 142, no. 5, pp. 1274–1283, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Agustin Cruz, E. M. Bauer, A. I. Rodriguez et al., “Chronic hypoxia induces right heart failure in caveolin-1−/− mice,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 302, no. 12, pp. H2518–H2527, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. W. Steudel, M. Scherrer-Crosbie, K. D. Bloch et al., “Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase,” The Journal of Clinical Investigation, vol. 101, no. 11, pp. 2468–2477, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. S.-F. Yet, M. A. Perrella, M. D. Layne et al., “Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice,” The Journal of Clinical Investigation, vol. 103, no. 8, pp. R23–R29, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Adegunsoye and S. Ramachandran, “Etiopathogenetic mechanisms of pulmonary hypertension in sleep-related breathing disorders,” Pulmonary Medicine, vol. 2012, Article ID 273591, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Hama, H. Itoh, G. Shirakami et al., “Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction,” Circulation, vol. 92, no. 6, pp. 1558–1564, 1995. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Fijalkowska, M. Kurzyna, A. Torbicki et al., “Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension,” Chest, vol. 129, no. 5, pp. 1313–1321, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. H. H. Leuchte, M. El Nounou, J. C. Tuerpe et al., “N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension,” Chest, vol. 131, no. 2, pp. 402–409, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. K. G. Blyth, B. A. Groenning, P. B. Mark et al., “NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension,” European Respiratory Journal, vol. 29, no. 4, pp. 737–744, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Jatti, R. Paisey, and R. More, “Coronary artery disease in Alström syndrome,” European Journal of Human Genetics, vol. 20, no. 1, pp. 117–118, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. M. A. Loudon, N. G. Bellenger, C. M. Carey, and R. B. Paisey, “Cardiac magnetic resonance imaging in Alström syndrome,” Orphanet Journal of Rare Diseases, vol. 4, no. 1, article 14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. D. Mozaffarian, E. J. Benjamin, A. S. Go et al., “Heart disease and stroke statistics—2015 update: a report from the American Heart Association,” Circulation, vol. 131, no. 4, pp. e29–e322, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. D. D. Schocken, E. J. Benjamin, G. C. Fonarow et al., “Prevention of heart failure: a scientific statement from the American Heart Association Councils on epidemiology and prevention, clinical cardiology, cardiovascular nursing, and high blood pressure research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group,” Circulation, vol. 117, no. 19, pp. 2544–2565, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. P. A. McCullough, E. F. Philbin, J. A. Spertus, S. Kaatz, K. R. Sandberg, and W. D. Weaver, “Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study,” Journal of the American College of Cardiology, vol. 39, no. 1, pp. 60–69, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. A. L. Bui, T. B. Horwich, and G. C. Fonarow, “Epidemiology and risk profile of heart failure,” Nature Reviews Cardiology, vol. 8, no. 1, pp. 30–41, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. D. S. Kim, “Acute exacerbations in patients with idiopathic pulmonary fibrosis,” Respiratory Research, vol. 14, article 86, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. B. Ley, H. R. Collard, and T. E. King Jr., “Clinical course and prediction of survival in idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 4, pp. 431–440, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Kee and M. T. Naughton, “Heart failure and the lung,” Circulation Journal, vol. 74, no. 12, pp. 2507–2516, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. J.-F. Jasmin, A. Calderone, T.-K. Leung, L. Villeneuve, and J. Dupuis, “Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan,” Cardiovascular Research, vol. 58, no. 3, pp. 621–631, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. W. Huang, M. P. Kingsbury, M. A. Turner, J. L. Donnelly, N. A. Flores, and D. J. Sheridan, “Capillary filtration is reduced in lungs adapted to chronic heart failure: morphological and haemodynamic correlates,” Cardiovascular Research, vol. 49, no. 1, pp. 207–217, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. K. Tsukimoto, O. Mathieu-Costello, R. Prediletto, A. R. Elliott, and J. B. West, “Ultrastructural appearances of pulmonary capillaries at high transmural pressures,” Journal of Applied Physiology, vol. 71, no. 2, pp. 573–582, 1991. View at Google Scholar · View at Scopus
  53. M. L. Costello, O. Mathieu-Costello, and J. B. West, “Stress failure of alveolar epithelial cells studied by scanning electron microscopy,” American Review of Respiratory Disease, vol. 145, no. 6, pp. 1446–1455, 1992. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Nanjo, Y. Yamashiro, S. Fujimoto et al., “Evaluation of sympathetic activity by 123I-metaiodobenzylguanidine myocardial scintigraphy in dilated cardiomyopathy patients with sleep breathing disorder,” Circulation Journal, vol. 73, no. 4, pp. 686–690, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Javaheri, R. Shukla, H. Zeigler, and L. Wexler, “Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in systolic heart failure,” Journal of the American College of Cardiology, vol. 49, no. 20, pp. 2028–2034, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Javaheri, “Sleep disorders in systolic heart failure: a prospective study of 100 male patients. The final report,” International Journal of Cardiology, vol. 106, no. 1, pp. 21–28, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. D. D. Sin, F. Fitzgerald, J. D. Parker, G. Newton, J. S. Floras, and T. D. Bradley, “Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure,” American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 4, pp. 1101–1106, 1999. View at Publisher · View at Google Scholar · View at Scopus
  58. H. W. Duchna, “Sleep-related breathing disorders—a second edition of the International Classification of Sleep Disorders (ICSD-2) of the American Academy of Sleep Medicine (AASM),” Pneumologie, vol. 60, pp. 568–575, 2006. View at Google Scholar
  59. M. J. Sateia, “International classification of sleep disorders-third edition: highlights and modifications,” Chest, vol. 146, no. 5, pp. 1387–1394, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Rasche and M. Orth, “Sleep and breathing in idiopathic pulmonary fibrosis,” Journal of Physiology and Pharmacology, vol. 60, supplement 5, pp. 13–14, 2009. View at Google Scholar · View at Scopus
  61. R. W. Light and R. B. George, “Serial pulmonary function in patients with acute heart failure,” Archives of Internal Medicine, vol. 143, no. 3, pp. 429–433, 1983. View at Publisher · View at Google Scholar · View at Scopus
  62. K. K. Iversen, J. Kjaergaard, D. Akkan et al., “Chronic obstructive pulmonary disease in patients admitted with heart failure,” Journal of Internal Medicine, vol. 264, no. 4, pp. 361–369, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. K. K. Iversen, J. Kjaergaard, D. Akkan et al., “The prognostic importance of lung function in patients admitted with heart failure,” European Journal of Heart Failure, vol. 12, no. 7, pp. 685–691, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. T. P. Olson, K. C. Beck, J. B. Johnson, and B. D. Johnson, “Competition for intrathoracic space reduces lung capacity in patients with chronic heart failure: a radiographic study,” Chest, vol. 130, no. 1, pp. 164–171, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. T. J. Huie, A. L. Olson, G. P. Cosgrove et al., “A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes,” Respirology, vol. 15, no. 6, pp. 909–917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. V. Ambrosini, A. Cancellieri, M. Chilosi et al., “Acute exacerbation of idiopathic pulmonary fibrosis: report of a series,” European Respiratory Journal, vol. 22, no. 5, pp. 821–826, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Churg, N. L. Müller, C. I. S. Silva, and J. L. Wright, “Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias,” The American Journal of Surgical Pathology, vol. 31, no. 2, pp. 277–284, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. I.-N. Park, D. S. Kim, T. S. Shim et al., “Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis,” Chest, vol. 132, no. 1, pp. 214–220, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. Miyazaki, T. Tateishi, T. Akashi, Y. Ohtani, N. Inase, and Y. Yoshizawa, “Clinical predictors and histologic appearance of acute exacerbations in chronic hypersensitivity pneumonitis,” Chest, vol. 134, no. 6, pp. 1265–1270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Suda, Y. Kaida, Y. Nakamura et al., “Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases,” Respiratory Medicine, vol. 103, no. 6, pp. 846–853, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. A. L. Olson, T. J. Huie, S. D. Groshong et al., “Acute exacerbations of fibrotic hypersensitivity pneumonitis: a case series,” Chest, vol. 134, no. 4, pp. 844–850, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. F. Luppi, S. Cerri, S. Taddei, G. Ferrara, and V. Cottin, “Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review,” Internal and Emergency Medicine, vol. 10, no. 4, pp. 401–411, 2015. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Rabinovitch, “Pulmonary hypertension: updating a mysterious disease,” Cardiovascular Research, vol. 34, no. 2, pp. 268–272, 1997. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Humbert, O. Sitbon, and G. Simonneau, “Treatment of pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 351, no. 14, pp. 1425–1473, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. P. Steele, G. Strange, J. Wlodarczyk et al., “Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?” BMC Cardiovascular Disorders, vol. 10, article 9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Campo, S. C. Mathai, J. Le Pavec et al., “Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension,” European Respiratory Journal, vol. 38, no. 2, pp. 359–367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. B. Sztrymf, R. Souza, L. Bertoletti et al., “Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension,” European Respiratory Journal, vol. 35, no. 6, pp. 1286–1293, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. F. Haddad, T. Peterson, E. Fuh et al., “Characteristics and outcome after hospitalization for acute right heart failure in patients with pulmonary arterial hypertension,” Circulation: Heart Failure, vol. 4, no. 6, pp. 692–699, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. J. T. Shin and M. J. Semigran, “Heart failure and pulmonary hypertension,” Heart Failure Clinics, vol. 6, no. 2, pp. 215–222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. N. Galie, M. M. Hoeper, M. Humbert et al., “Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT),” European Heart Journal, vol. 30, pp. 2493–2537, 2009. View at Google Scholar
  81. N. Galiè, P. A. Corris, A. Frost et al., “Updated treatment algorithm of pulmonary arterial hypertension,” Journal of the American College of Cardiology, vol. 62, no. 25, pp. D60–D72, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. W. Seeger, Y. Adir, J. A. Barberà et al., “Pulmonary hypertension in chronic lung diseases,” Journal of the American College of Cardiology, vol. 62, no. 25, pp. D109–D116, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. T. E. King Jr., J. Behr, K. K. Brown et al., “BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 1, pp. 75–81, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. T. E. King Jr., K. K. Brown, G. Raghu et al., “BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 1, pp. 92–99, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. G. Raghu, R. Million-Rousseau, A. Morganti et al., “Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial,” European Respiratory Journal, vol. 42, no. 6, pp. 1622–1632, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. G. Raghu, J. Behr, K. K. Brown et al., “Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial,” Annals of Internal Medicine, vol. 158, no. 9, pp. 641–649, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. T. J. Corte, G. J. Keir, K. Dimopoulos et al., “Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia,” American Journal of Respiratory and Critical Care Medicine, vol. 190, no. 2, pp. 208–217, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. M. K. Han, D. S. Bach, P. G. Hagan et al., “Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction,” Chest, vol. 143, pp. 1699–1708, 2013. View at Google Scholar
  89. M. M. Hoeper, M. Halank, H. Wilkens et al., “Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial,” European Respiratory Journal, vol. 41, no. 4, pp. 853–860, 2013. View at Publisher · View at Google Scholar · View at Scopus
  90. G. Raghu, B. Rochwerg, Y. Zhang et al., “An official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An Update of the 2011 Clinical Practice Guideline,” American Journal of Respiratory and Critical Care Medicine, vol. 192, no. 2, pp. e3–e19, 2015. View at Publisher · View at Google Scholar
  91. G. Raghu, H. R. Collard, J. J. Egan et al., “An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 6, pp. 788–824, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. N. Demir, A. Şahin, O. Küçükşahin et al., “Pulmonary arterial hypertension and systemic sclerosis relation: a single centre experience,” Heart Lung and Circulation, vol. 23, no. 7, pp. 667–673, 2014. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Le Pavec, R. E. Girgis, N. Lechtzin et al., “Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies,” Arthritis & Rheumatism, vol. 63, no. 8, pp. 2456–2464, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. H.-A. Ghofrani, A. M. D'Armini, F. Grimminger et al., “Riociguat for the treatment of chronic thromboembolic pulmonary hypertension,” The New England Journal of Medicine, vol. 369, no. 4, pp. 319–329, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. H.-A. Ghofrani, N. Galiè, F. Grimminger et al., “Riociguat for the treatment of pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 369, no. 4, pp. 330–340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. H. A. Ghofrani, M. M. Hoeper, M. Halank et al., “Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study,” European Respiratory Journal, vol. 36, no. 4, pp. 792–799, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. F. Grimminger, G. Weimann, R. Frey et al., “First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension,” European Respiratory Journal, vol. 33, no. 4, pp. 785–792, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Rich, E. Kaufmann, and P. S. Levy, “The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension,” The New England Journal of Medicine, vol. 327, no. 2, pp. 76–81, 1992. View at Publisher · View at Google Scholar · View at Scopus
  99. D. Giannessi, S. Del Ry, and R. L. Vitale, “The role of endothelins and their receptors in heart failure,” Pharmacological Research, vol. 43, no. 2, pp. 111–126, 2001. View at Publisher · View at Google Scholar · View at Scopus
  100. R. J. Cody, G. J. Haas, P. F. Binkley, Q. Capers, and R. Kelley, “Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure,” Circulation, vol. 85, no. 2, pp. 504–509, 1992. View at Publisher · View at Google Scholar · View at Scopus
  101. S. Sakai, T. Miyauchi, T. Sakurai et al., “Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: marked increase in endothelin-1 production in the failing heart,” Circulation, vol. 93, no. 6, pp. 1214–1222, 1996. View at Publisher · View at Google Scholar · View at Scopus
  102. D. J. Stewart, R. D. Levy, P. Cernacek, and D. Langleben, “Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?” Annals of Internal Medicine, vol. 114, no. 6, pp. 464–469, 1991. View at Publisher · View at Google Scholar · View at Scopus
  103. P. I. Anand, P. J. McMurray, P. J. N. Cohn et al., “Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 364, no. 9431, pp. 347–354, 2004. View at Publisher · View at Google Scholar · View at Scopus
  104. R. N. Channick, G. Simonneau, O. Sitbon et al., “Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study,” The Lancet, vol. 358, no. 9288, pp. 1119–1123, 2001. View at Publisher · View at Google Scholar · View at Scopus
  105. N. Galiè, L. Rubin, M. Hoeper et al., “Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial,” The Lancet, vol. 371, no. 9630, pp. 2093–2100, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Humbert, E. S. Segal, D. G. Kiely, J. Carlsen, B. Schwierin, and M. M. Hoeper, “Results of European post-marketing surveillance of bosentan in pulmonary hypertension,” European Respiratory Journal, vol. 30, no. 2, pp. 338–344, 2007. View at Publisher · View at Google Scholar · View at Scopus
  107. A. M. Wolfson, N. Steiger, and M. Gomberg-Maitland, “New pharmacotherapies for pulmonary hypertension: where do they fit in?” Current Hypertension Reports, vol. 16, no. 12, pp. 1–10, 2014. View at Publisher · View at Google Scholar · View at Scopus
  108. O. Ben-Yehuda, D. Pizzuti, A. Brown et al., “Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension,” Journal of the American College of Cardiology, vol. 60, no. 1, pp. 80–81, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. N. Galiè, H. Olschewski, R. J. Oudiz et al., “Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2,” Circulation, vol. 117, no. 23, pp. 3010–3019, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. T. Pulido, I. Adzerikho, R. N. Channick et al., “Macitentan and morbidity and mortality in pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 369, no. 9, pp. 809–818, 2013. View at Publisher · View at Google Scholar · View at Scopus
  111. H. Olschewski, F. Rose, R. Schermuly et al., “Prostacyclin and its analogues in the treatment of pulmonary hypertension,” Pharmacology and Therapeutics, vol. 102, no. 2, pp. 139–153, 2004. View at Publisher · View at Google Scholar · View at Scopus
  112. Y. Yui, H. Nakajima, C. Kawai, and T. Murakami, “Prostacyclin therapy in patients with congestive heart failure,” The American Journal of Cardiology, vol. 50, no. 2, pp. 320–324, 1982. View at Publisher · View at Google Scholar · View at Scopus
  113. O. Sitbon, M. Humbert, H. Nunes et al., “Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival,” Journal of the American College of Cardiology, vol. 40, no. 4, pp. 780–788, 2002. View at Publisher · View at Google Scholar · View at Scopus
  114. V. V. McLaughlin, A. Shillington, and S. Rich, “Survival in primary pulmonary hypertension: the impact of epoprostenol therapy,” Circulation, vol. 106, no. 12, pp. 1477–1482, 2002. View at Publisher · View at Google Scholar · View at Scopus
  115. R. Agarwal and M. Gomberg-Maitland, “Current therapeutics and practical management strategies for pulmonary arterial hypertension,” American Heart Journal, vol. 162, no. 2, pp. 201–213, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. K. M. Chin, D. B. Badesch, I. M. Robbins et al., “Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME−1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study,” American Heart Journal, vol. 167, no. 2, pp. 218–225.e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  117. G. Simonneau, R. J. Barst, N. Galie et al., “Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial,” American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 6, pp. 800–804, 2002. View at Publisher · View at Google Scholar · View at Scopus
  118. R. J. Barst, N. Galie, R. Naeije et al., “Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil,” European Respiratory Journal, vol. 28, no. 6, pp. 1195–1203, 2006. View at Publisher · View at Google Scholar · View at Scopus
  119. V. F. Tapson, M. Gomberg-Maitland, V. V. McLaughlin et al., “Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial,” Chest, vol. 129, no. 3, pp. 683–688, 2006. View at Publisher · View at Google Scholar · View at Scopus
  120. H. Olschewski, G. Simonneau, N. Galiè et al., “Inhaled iloprost for severe pulmonary hypertension,” The New England Journal of Medicine, vol. 347, no. 5, pp. 322–329, 2002. View at Publisher · View at Google Scholar · View at Scopus
  121. Y. Wu, D. S. O'Callaghan, and M. Humbert, “An update on medical therapy for pulmonary arterial hypertension,” Current Hypertension Reports, vol. 15, no. 6, pp. 614–622, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. R. J. Barst, M. McGoon, V. McLaughlin et al., “Beraprost therapy for pulmonary arterial hypertension,” Journal of the American College of Cardiology, vol. 41, pp. 2119–2125, 2003. View at Google Scholar
  123. C. A. Sueta, M. Gheorghiade, K. F. Adams Jr. et al., “Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group,” The American Journal of Cardiology, vol. 75, no. 3, pp. 34A–43A, 1995. View at Publisher · View at Google Scholar · View at Scopus
  124. R. M. Califf, K. F. Adams, W. J. McKenna, and et al, “A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST),” The American Heart Journal, vol. 134, no. 1, pp. 44–54, 1997. View at Publisher · View at Google Scholar · View at Scopus
  125. S. I. McFarlane, N. Winer, and J. R. Sowers, “Role of the natriuretic peptide system in cardiorenal protection,” Archives of Internal Medicine, vol. 163, no. 22, pp. 2696–2704, 2003. View at Publisher · View at Google Scholar · View at Scopus
  126. N. Galiè, H. A. Ghofrani, A. Torbicki et al., “Sildenafil citrate therapy for pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 353, no. 20, pp. 2148–2157, 2005. View at Publisher · View at Google Scholar · View at Scopus
  127. R. B. Moreland, I. Goldstein, N. N. Kim, and A. Traish, “Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: research and clinical implications in erectile dysfunction,” Trends in Endocrinology and Metabolism, vol. 10, no. 3, pp. 97–104, 1999. View at Publisher · View at Google Scholar · View at Scopus
  128. N. Galiè, B. H. Brundage, H. A. Ghofrani et al., “Tadalafil therapy for pulmonary arterial hypertension,” Circulation, vol. 119, no. 22, pp. 2894–2903, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. A. Dasgupta, L. Bowman, C. D'Arsigny, and S. Archer, “Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,” Clinical Pharmacology & Therapeutics, vol. 97, no. 1, pp. 88–102, 2015. View at Publisher · View at Google Scholar
  130. Y. Fukumoto, T. Matoba, A. Ito et al., “Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension,” Heart, vol. 91, no. 3, pp. 391–392, 2005. View at Publisher · View at Google Scholar · View at Scopus
  131. K. Ishikura, N. Yamada, M. Ito et al., “Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension,” Circulation Journal, vol. 70, no. 2, pp. 174–178, 2006. View at Publisher · View at Google Scholar · View at Scopus
  132. R. Jiang, Z. S. Ai, X. Jiang et al., “Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension,” Hypertension Research, vol. 38, no. 8, pp. 539–544, 2015. View at Publisher · View at Google Scholar
  133. L. Taraseviciene-Stewart, R. Scerbavicius, K.-H. Choe et al., “Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 291, no. 4, pp. L668–L676, 2006. View at Publisher · View at Google Scholar · View at Scopus
  134. S. M. Kawut, E. Bagiella, D. J. Lederer et al., “Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT,” Circulation, vol. 123, no. 25, pp. 2985–2993, 2011. View at Publisher · View at Google Scholar · View at Scopus
  135. L. Zhao, C.-N. Chen, N. Hajji et al., “Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid,” Circulation, vol. 126, no. 4, pp. 455–467, 2012. View at Publisher · View at Google Scholar · View at Scopus
  136. H. J. Bogaard, S. Mizuno, A. A. Al Hussaini et al., “Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 10, pp. 1402–1410, 2011. View at Publisher · View at Google Scholar · View at Scopus
  137. W. Plazak, K. Gryga, J. Sznajd et al., “Reactivity of pulmonary circulation and right ventricle function to inhaled nitric oxide in systemic sclerosis patients,” Clinical Rheumatology, vol. 31, no. 1, pp. 99–104, 2012. View at Publisher · View at Google Scholar · View at Scopus
  138. S. Miyamichi-Yamamoto, Y. Fukumoto, K. Sugimura et al., “Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease,” Circulation Journal, vol. 75, no. 11, pp. 2668–2674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  139. X. Jais, D. Launay, A. Yaici et al., “Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases,” Arthritis & Rheumatism, vol. 58, no. 2, pp. 521–531, 2008. View at Publisher · View at Google Scholar · View at Scopus
  140. O. Sanchez, O. Sitbon, X. Jaï'S, G. Simonneau, and M. Humbert, “Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension,” Chest, vol. 130, no. 1, pp. 182–189, 2006. View at Publisher · View at Google Scholar · View at Scopus
  141. A. Dhala, “Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction,” Clinical and Developmental Immunology, vol. 2012, Article ID 854941, 12 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  142. N. Galiè, M. Humbert, J.-L. Vachiéry et al., “Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial,” Journal of the American College of Cardiology, vol. 39, no. 9, pp. 1496–1502, 2002. View at Publisher · View at Google Scholar · View at Scopus
  143. Z.-C. Jing, K. Parikh, T. Pulido et al., “Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial,” Circulation, vol. 127, no. 5, pp. 624–633, 2013. View at Publisher · View at Google Scholar · View at Scopus
  144. N. Skoro-Sajer and I. M. Lang, “Selexipag for the treatment of pulmonary arterial hypertension,” Expert Opinion on Pharmacotherapy, vol. 15, no. 3, pp. 429–436, 2014. View at Publisher · View at Google Scholar · View at Scopus
  145. S. Bruderer, N. Hurst, P. Kaufmann, and J. Dingemanse, “Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects,” Pharmacology, vol. 94, no. 3-4, pp. 148–156, 2014. View at Publisher · View at Google Scholar
  146. Z.-C. Jing, Z.-X. Yu, J.-Y. Shen et al., “Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 12, pp. 1723–1729, 2011. View at Publisher · View at Google Scholar · View at Scopus
  147. Y.-F. Fan, R. Zhang, X. Jiang et al., “The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension,” Cardiovascular Research, vol. 99, no. 3, pp. 395–403, 2013. View at Publisher · View at Google Scholar · View at Scopus
  148. M. J. Overbeek, G. P. van Nieuw Amerongen, A. Boonstra, E. F. Smit, and A. Vonk-Noordegraaf, “Possible role of imatinib in clinical pulmonary veno-occlusive disease,” European Respiratory Journal, vol. 32, no. 1, pp. 232–235, 2008. View at Publisher · View at Google Scholar · View at Scopus
  149. K. C. Patterson, A. Weissmann, T. Ahmadi, and H. W. Farber, “Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension,” Annals of Internal Medicine, vol. 145, no. 2, pp. 152–153, 2006. View at Publisher · View at Google Scholar · View at Scopus
  150. R. Souza, O. Sitbon, F. Parent, G. Simonneau, and M. Humbert, “Long term imatinib treatment in pulmonary arterial hypertension,” Thorax, vol. 61, article 736, 2006. View at Publisher · View at Google Scholar · View at Scopus
  151. H.-A. Ghofrani, N. W. Morrell, M. M. Hoeper et al., “Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 9, pp. 1171–1177, 2010. View at Publisher · View at Google Scholar · View at Scopus
  152. M. M. Hoeper, R. J. Barst, R. C. Bourge et al., “Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study,” Circulation, vol. 127, no. 10, pp. 1128–1138, 2013. View at Publisher · View at Google Scholar · View at Scopus
  153. J. M. Edelberg, S. H. Lee, M. Kaur et al., “Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart,” Circulation, vol. 105, no. 5, pp. 608–613, 2002. View at Publisher · View at Google Scholar · View at Scopus
  154. P. C. H. Hsieh, C. MacGillivray, J. Gannon, F. U. Cruz, and R. T. Lee, “Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity,” Circulation, vol. 114, no. 7, pp. 637–644, 2006. View at Publisher · View at Google Scholar · View at Scopus
  155. S. Farha, R. Dweik, F. Rahaghi et al., “Imatinib in pulmonary arterial hypertension: c-Kit inhibition,” Pulmonary Circulation, vol. 4, no. 3, pp. 452–455, 2014. View at Publisher · View at Google Scholar
  156. T. E. King Jr., W. Z. Bradford, S. Castro-Bernardini et al., “A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis,” The New England Journal of Medicine, vol. 370, no. 22, pp. 2083–2092, 2014. View at Publisher · View at Google Scholar · View at Scopus
  157. L. Richeldi, R. M. du Bois, G. Raghu et al., “Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis,” The New England Journal of Medicine, vol. 370, no. 22, pp. 2071–2082, 2014. View at Publisher · View at Google Scholar · View at Scopus
  158. D. Valeyre, C. Albera, W. Z. Bradford et al., “Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis,” Respirology, vol. 19, no. 5, pp. 740–747, 2014. View at Publisher · View at Google Scholar · View at Scopus
  159. Y. Wang, Y. Wu, J. Chen, S. Zhao, and H. Li, “Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 Inflammasome formation,” Cardiology, vol. 126, no. 1, pp. 1–11, 2013. View at Publisher · View at Google Scholar · View at Scopus
  160. D. T. Nguyen, C. Ding, E. Wilson, G. M. Marcus, and J. E. Olgin, “Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias,” Heart Rhythm, vol. 7, no. 10, pp. 1438–1445, 2010. View at Publisher · View at Google Scholar · View at Scopus
  161. R. Ramos-Mondragón, C. A. Galindo, M. García-Castañeda et al., “Chronic potentiation of cardiac L-type Ca2+ channels by pirfenidone,” Cardiovascular Research, vol. 96, no. 2, pp. 244–254, 2012. View at Publisher · View at Google Scholar · View at Scopus
  162. T. Yamazaki, N. Yamashita, Y. Izumi et al., “The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice,” Hypertension Research, vol. 35, no. 1, pp. 34–40, 2012. View at Publisher · View at Google Scholar · View at Scopus
  163. H. J. Bogaard, K. Abe, A. V. Noordegmaf, and N. F. Voelkel, “The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension,” Chest, vol. 135, no. 3, pp. 794–804, 2009. View at Publisher · View at Google Scholar · View at Scopus
  164. M. Guglin and S. Verma, “Right side of heart failure,” Heart Failure Reviews, vol. 17, no. 3, pp. 511–527, 2012. View at Publisher · View at Google Scholar · View at Scopus
  165. M. C. van de Veerdonk, T. Kind, J. T. Marcus et al., “Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy,” Journal of the American College of Cardiology, vol. 58, no. 24, pp. 2511–2519, 2011. View at Publisher · View at Google Scholar · View at Scopus
  166. J. Gomez-Arroyo, J. Sandoval, M. A. Simon, E. Dominguez-Cano, N. F. Voelkel, and H. J. Bogaard, “Treatment for pulmonary arterial hypertension-associated right ventricular dysfunction,” Annals of the American Thoracic Society, vol. 11, no. 7, pp. 1101–1115, 2014. View at Publisher · View at Google Scholar · View at Scopus
  167. A. Ciarka, V. Doan, S. Velez-Roa, R. Naeije, and P. Van De Borne, “Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension,” The American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 11, pp. 1269–1275, 2010. View at Publisher · View at Google Scholar · View at Scopus
  168. M. R. Bristow, W. Minobe, R. Rasmussen et al., “Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms,” The Journal of Clinical Investigation, vol. 89, no. 3, pp. 803–815, 1992. View at Publisher · View at Google Scholar · View at Scopus
  169. S. Provencher, P. Herve, X. Jais et al., “Deleterious effects of β-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension,” Gastroenterology, vol. 130, no. 1, pp. 120–126, 2006. View at Publisher · View at Google Scholar · View at Scopus
  170. S. Reiken, X. H. T. Wehrens, J. A. Vest et al., “β-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure,” Circulation, vol. 107, no. 19, pp. 2459–2466, 2003. View at Publisher · View at Google Scholar · View at Scopus
  171. J. Tongers, B. Schwerdtfeger, G. Klein et al., “Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension,” American Heart Journal, vol. 153, no. 1, pp. 127–132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  172. I.-M. Kim, D. G. Tilley, J. Chen et al., “β-blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 38, pp. 14555–14560, 2008. View at Publisher · View at Google Scholar · View at Scopus
  173. J. I. Drake, H. J. Bogaard, S. Mizuno et al., “Molecular signature of a right heart failure program in chronic severe pulmonary hypertension,” American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 6, pp. 1239–1247, 2011. View at Publisher · View at Google Scholar · View at Scopus
  174. H. J. Bogaard, R. Natarajan, S. Mizuno et al., “Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 5, pp. 652–660, 2010. View at Publisher · View at Google Scholar · View at Scopus
  175. K. Okumura, H. Kato, O. Honjo et al., “Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension,” Journal of Molecular Medicine, vol. 93, no. 6, pp. 663–674, 2015. View at Publisher · View at Google Scholar · View at Scopus
  176. F. S. de Man, M. L. Handoko, J. J. M. van Ballegoij et al., “Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension,” Circulation: Heart Failure, vol. 5, no. 1, pp. 97–105, 2012. View at Publisher · View at Google Scholar · View at Scopus
  177. L. Piao, Y.-H. Fang, K. S. Parikh et al., “GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension,” Circulation, vol. 126, no. 24, pp. 2859–2869, 2012. View at Publisher · View at Google Scholar · View at Scopus
  178. L. M. Casey, A. R. Pistner, S. L. Belmonte et al., “Small molecule disruption of Gβγ signaling inhibits the progression of heart failure,” Circulation Research, vol. 107, no. 4, pp. 532–539, 2010. View at Publisher · View at Google Scholar · View at Scopus
  179. H. Ikram, A. H. Maslowski, M. G. Nicholls, E. A. Espiner, and F. T. Hull, “Haemodynamic and hormonal effects of captopril in primary pulmonary hypertension,” British Heart Journal, vol. 48, no. 6, pp. 541–545, 1982. View at Publisher · View at Google Scholar · View at Scopus
  180. C. V. Leier, D. Bambach, S. Nelson et al., “Captopril in primary pulmonary hypertension,” Circulation, vol. 67, no. 1, pp. 155–161, 1983. View at Publisher · View at Google Scholar · View at Scopus
  181. M. U. Braun, P. Szalai, R. H. Strasser, and M. M. Borst, “Right ventricular hypertrophy and apoptosis after pulmonary artery banding: regulation of PKC isozymes,” Cardiovascular Research, vol. 59, no. 3, pp. 658–667, 2003. View at Publisher · View at Google Scholar · View at Scopus
  182. J. Gomez-Arroyo, S. Mizuno, K. Szczepanek et al., “Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension,” Circulation: Heart Failure, vol. 6, no. 1, pp. 136–144, 2013. View at Publisher · View at Google Scholar · View at Scopus
  183. Y.-H. Fang, L. Piao, Z. Hong et al., “Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle,” Journal of Molecular Medicine, vol. 90, no. 1, pp. 31–43, 2012. View at Publisher · View at Google Scholar · View at Scopus
  184. H. Ashrafian, M. P. Frenneaux, and L. H. Opie, “Metabolic mechanisms in heart failure,” Circulation, vol. 116, no. 4, pp. 434–448, 2007. View at Publisher · View at Google Scholar · View at Scopus
  185. H. J. Bogaard, R. Natarajan, S. C. Henderson et al., “Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure,” Circulation, vol. 120, no. 20, pp. 1951–1960, 2009. View at Publisher · View at Google Scholar · View at Scopus
  186. D. A. Mann and F. Oakley, “Serotonin paracrine signaling in tissue fibrosis,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1832, no. 7, pp. 905–910, 2013. View at Publisher · View at Google Scholar · View at Scopus
  187. K.-G. Shyu, “Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure?” Circulation Research, vol. 104, no. 1, pp. 1–3, 2009. View at Publisher · View at Google Scholar · View at Scopus
  188. O. Lairez, T. Cognet, S. Schaak et al., “Role of serotonin 5-HT2A receptors in the development of cardiac hypertrophy in response to aortic constriction in mice,” Journal of Neural Transmission, vol. 120, no. 6, pp. 927–935, 2013. View at Publisher · View at Google Scholar · View at Scopus
  189. W. Janssen, Y. Schymura, T. Novoyatleva et al., “5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure,” BioMed Research International, vol. 2015, Article ID 438403, 8 pages, 2015. View at Publisher · View at Google Scholar
  190. R. Hambrecht, E. Fiehn, C. Weigl et al., “Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure,” Circulation, vol. 98, no. 24, pp. 2709–2715, 1998. View at Publisher · View at Google Scholar · View at Scopus
  191. D. Mereles, N. Ehlken, S. Kreuscher et al., “Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension,” Circulation, vol. 114, no. 14, pp. 1482–1489, 2006. View at Publisher · View at Google Scholar · View at Scopus
  192. I. Goldenberg, V. Kutyifa, H. U. Klein et al., “Survival with cardiac-resynchronization therapy in mild heart failure,” The New England Journal of Medicine, vol. 370, no. 18, pp. 1694–1701, 2014. View at Publisher · View at Google Scholar · View at Scopus
  193. J. T. Marcus, C. T.-J. Gan, J. J. M. Zwanenburg et al., “Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling,” Journal of the American College of Cardiology, vol. 51, no. 7, pp. 750–757, 2008. View at Publisher · View at Google Scholar · View at Scopus
  194. M. L. Handoko, R. R. Lamberts, E. M. Redout et al., “Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 297, no. 5, pp. H1752–H1759, 2009. View at Publisher · View at Google Scholar · View at Scopus
  195. N. Espinola-Zavaleta, J. Vargas-Barrón, J. I. Tazar et al., “Echocardiographic evaluation of patients with primary pulmonary hypertension before and after atrial septostomy,” Echocardiography, vol. 16, no. 7, pp. 625–634, 1999. View at Publisher · View at Google Scholar · View at Scopus
  196. A. Ciarka, J.-L. Vachièry, A. Houssière et al., “Atrial septostomy decreases sympathetic overactivity in pulmonary arterial hypertension,” Chest, vol. 131, no. 6, pp. 1831–1837, 2007. View at Publisher · View at Google Scholar · View at Scopus
  197. M. Berman, S. Tsui, A. Vuylsteke, A. Klein, and D. P. Jenkins, “Life-threatening right ventricular failure in pulmonary hypertension: RVAD or ECMO?” Journal of Heart and Lung Transplantation, vol. 27, no. 10, pp. 1188–1189, 2008. View at Publisher · View at Google Scholar · View at Scopus
  198. M. Berman, S. Tsui, A. Vuylsteke et al., “Successful extracorporeal membrane oxygenation support after pulmonary thromboendarterectomy,” Annals of Thoracic Surgery, vol. 86, no. 4, pp. 1261–1267, 2008. View at Publisher · View at Google Scholar · View at Scopus
  199. K. Furukawa, T. Motomura, and Y. Nosé, “Right ventricular failure after left ventricular assist device implantation: the need for an implantable right ventricular assist device,” Artificial Organs, vol. 29, no. 5, pp. 369–377, 2005. View at Publisher · View at Google Scholar · View at Scopus
  200. J. K. Bhama, R. L. Kormos, Y. Toyoda, J. J. Teuteberg, K. R. McCurry, and M. P. Siegenthaler, “Clinical experience using the Levitronix CentriMag system for temporary right ventricular mechanical circulatory support,” Journal of Heart and Lung Transplantation, vol. 28, no. 9, pp. 971–976, 2009. View at Publisher · View at Google Scholar · View at Scopus
  201. G. M. Giesler, J. S. Gomez, G. Letsou, M. Vooletich, and R. W. Smalling, “Initial report of percutaneous right ventricular assist for right ventricular shock secondary to right ventricular infarction,” Catheterization and Cardiovascular Interventions, vol. 68, no. 2, pp. 263–266, 2006. View at Publisher · View at Google Scholar · View at Scopus
  202. A. W. Cheung, C. W. White, M. K. Davis, and D. H. Freed, “Short-term mechanical circulatory support for recovery from acute right ventricular failure: clinical outcomes,” The Journal of Heart and Lung Transplantation, vol. 33, no. 8, pp. 794–799, 2014. View at Publisher · View at Google Scholar · View at Scopus
  203. J. A. Goldstein and M. J. Kern, “Percutaneous mechanical support for the failing right heart,” Cardiology Clinics, vol. 30, no. 2, pp. 303–310, 2012. View at Publisher · View at Google Scholar · View at Scopus
  204. J. M. Schaffer, S. K. Singh, B. A. Reitz, R. T. Zamanian, and H. R. Mallidi, “Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need,” The Journal of the American Medical Association, vol. 313, no. 9, pp. 936–948, 2015. View at Publisher · View at Google Scholar
  205. L. U. Nwakanma, C. E. Simpkins, J. A. Williams et al., “Impact of bilateral versus single lung transplantation on survival in recipients 60 years of age and older: analysis of United Network for Organ Sharing database,” Journal of Thoracic and Cardiovascular Surgery, vol. 133, no. 2, pp. 541–547, 2007. View at Publisher · View at Google Scholar · View at Scopus
  206. S. Lehmann, M. Uhlemann, S. Leontyev et al., “Bilateral versus single lung transplant for idiopathic pulmonary fibrosis,” Experimental and Clinical Transplantation, vol. 12, pp. 443–447, 2014. View at Google Scholar